



## IBA Dosimetry launches myQA<sup>®</sup> Daily – a new solution for easy, efficient, and accurate morning QA

*myQA Daily is the only solution that enables fast as well as high-quality daily Linac QA. More measurement points allow more accurate morning checks and trend analysis.*

**San Antonio, TX, USA, October 18, 2018** – IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the market launch of myQA Daily at the ASTRO 2018 annual meeting.

myQA Daily is the first solution for daily Linac QA to combine workflow efficiency with high-quality measurements and analysis. With 125 ionization chambers overall, and 31 ionization chambers for each centerline, the detector array provides the largest amount of measured beam data of any available daily QA device. This increased data capacity allows a more accurate morning QA and trend analysis of dose output, flatness, symmetry, center, field size, and energy. With the higher accuracy of myQA Daily, negative trends and Linac issues can be detected before the Linac fails.

myQA Daily is optimized for daily QA workflow efficiency. From detector setup to measurement to test result, the entire morning QA can be completed in less than 5 minutes.

The myQA Daily software is operated easily in a web browser from any workstation or tablet PC connected to the hospital network. The server-based software enables easy integration with existing IT infrastructure.

The detector array's real-time Wi-Fi data exchange and rechargeable battery allow wireless daily QA setup and measurements. The cable-free design enables a convenient workflow and easy use at multiple Linacs.

Press release | 18/10/2018

**IBA | Dosimetry GmbH**

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10  
Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262  
Managing Directors (Geschäftsführer): Olivier Legrain, Jean-Marc Bothy, Soumya Chandramouli  
[Dosimetry-info@iba-group.com](mailto:Dosimetry-info@iba-group.com) | [www.iba-dosimetry.com](http://www.iba-dosimetry.com)

PROTECT +  
ENHANCE +  
SAVE LIVES



*“The morning QA is an essential step to ensure patient safety and the accuracy of the Linac every day before the first patient is treated. Therefore we developed myQA Daily in a way to provide the highest possible accuracy for morning QA,”* said **Jean-Marc Bothy, President of IBA Dosimetry GmbH**. *“The high accuracy and efficient workflow make myQA Daily the new standard in morning QA.”*

To find out more please visit [iba-dosimetry.com](http://iba-dosimetry.com)

\*\*\*ends\*\*\*

### **About IBA Dosimetry**

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at [iba-dosimetry.com](http://iba-dosimetry.com)

### **About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at [iba-worldwide.com](http://iba-worldwide.com)

### **Media Contact:**

Ralf Schira, Director Global Marketing, IBA Dosimetry, [ralf.schira@iba-group.com](mailto:ralf.schira@iba-group.com)

Press release | 18/10/2018

**IBA | Dosimetry GmbH**

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10

Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262

Managing Directors (Geschäftsführer): Olivier Legrain, Jean-Marc Bothy, Soumya Chandramouli

[Dosimetry-info@iba-group.com](mailto:Dosimetry-info@iba-group.com) | [www.iba-dosimetry.com](http://www.iba-dosimetry.com)

**PROTECT +  
ENHANCE +  
SAVE LIVES**